In chronic myeloid leukemia, the ability of the leukemia stem cells to choose from the many fates that are available to normal hematopoietic stem cells appears to be deregulated by BCR-ABLp210 and changes to the epigenome are also important. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.